100 completed, 13 unknown, 11 terminated, 4 withdrawn. 45 Phase 4, 31 Phase 3, 24 Phase 2, 16 Not applicable, 11 Phase 1.
Follow Brimonidine Tartrate: new trials by email Literature Review of Brimonidine Tartrate trials Research Report on Brimonidine Tartrate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution - Glaucoma, Glaucoma, Open-Angle | Phase 4 | Not yet recruiting | Tulane University | 60 | 2027-11-01 | 2026-10-13 |
| Upneeq vs. Lumify Ptosis Oxymetazoline 0.1% (Upneeq), Brimonidine 0.025% (Lumify) - Acquired Ptosis | Phase 4 | Not yet recruiting | Duke University | 50 | 2026-12-01 | 2026-05-22 |
| A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness BTOS-HA, Lumify® - Ocular Redness | Phase 3 | Completed | Bausch & Lomb Incorporated | 578 | 2025-05-22 | 2026-05-28 |
| Brimonidine 0.33% for Rosacea-Related Facial Erythema Brimonidine 0.33% gel, Placebo gel - Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic) | Phase 4 | Completed | Istanbul Training and Research Hospital | 45 | 2025-05-01 | 2026-02-24 |
| Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost Netarsudil, Brimonidine - Normal Tension Glaucoma | Phase 4 | Completed | Westlake Eye Specialists | 100 | 2024-06-13 | 2025-10-22 |
| Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia LNZ101 (Aceclidine /Brimonidine) ophthalmic solution, LNZ100 (Aceclidine) ophthalmic solution, Placebo (Vehicle) ophthalmic solution - Presbyopia | Phase 1 | Completed | Corxel Pharmaceuticals | 21 | 2024-03-04 | 2024-04-23 |
| Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia Aceclidine + Brimonidine, Aceclidine - Eye Diseases, Presbyopia | Phase 1 | Completed | LENZ Therapeutics, Inc | 30 | 2023-07-06 | 2023-10-16 |
| Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 512 | 2023-04-20 | 2025-07-10 |
| Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Brimonidine - Presbyopia, Refractive Error | Phase 3 | Completed | LENZ Therapeutics, Inc | 469 | 2022-12-19 | 2026-05-13 |
| Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025% - Seasonal Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 229 | 2022-11-18 | 2025-07-01 |
| Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035% - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 188 | 2022-10-12 | 2025-02-14 |
| Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle proprietary ophthalmic solution - Presbyopia, Refractive Errors | Phase 2 | Completed | LENZ Therapeutics, Inc | 59 | 2022-08-06 | 2024-09-05 |
| Brimonidine for Intraoperative Hemostasis Brimonidine Topical - Dermatochalasis of Eyelid, Ptosis, Eyelid | Phase 4 | Withdrawn | University of Louisville | 2022-05-26 | 2025-01-15 | |
| "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness" Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation, Lumify® (brimonidine tartrate ophthalmic solution 0.025%) - Ocular Redness | Phase 3 | Completed | Bausch & Lomb Incorporated | 380 | 2022-05-13 | 2024-08-26 |
| Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle Proprietary Ophthalmic Solution - Presbyopia, Refractive Errors | Phase 2 | Completed | LENZ Therapeutics, Inc | 68 | 2022-05-05 | 2024-09-05 |
| Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia BRIMOCHOL™ PF, Carbachol PF, Brimonidine tartrate - Presbyopia | Phase 3 | Completed | Visus Therapeutics | 182 | 2022-03-30 | 2024-10-15 |
| Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia BRIMOCHOL™ PF, Carbachol PF, Vehicle - Presbyopia | Phase 3 | Completed | Visus Therapeutics | 629 | 2022-03-15 | 2025-08-06 |
| Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive BRIDIN-plus Eye drops, Combigan Eye drops - Glaucoma, Ocular Hypertensive | Phase 4 | Completed | CHA University | 60 | 2021-10-08 | 2025-03-26 |
| Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound - Presbyopia | Phase 1 | Unknown | Optall Vision | 11 | 2021-08-14 | 2021-08-17 |
| Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac, Pilocarpine Hydrochloride, Brimonidine Tartrate - Presbyopia | Phase 1 | Unknown | Optall Vision | 11 | 2021-08-10 | 2021-08-19 |
Showing 20 of 130. Sign in to see all of them.
Glaucoma (35) · Ocular Hypertension (34) · Glaucoma, Open-Angle (29) · Presbyopia (12) · Low Tension Glaucoma (6) · Rosacea (6) · Eye Diseases (5) · Blepharoptosis (4) · Macular Degeneration (4) · Refractive Errors (4) · Diabetic Retinopathy (3) · Dry Eye Syndromes (3) · Glaucoma, Angle-Closure (3) · Hyperemia (3) · Myopia (3)
Allergan (23) · Alcon Research (14) · Bausch & Lomb Incorporated (8) · Galderma R&D (4) · LENZ Therapeutics, Inc (4) · Massachusetts Eye and Ear Infirmary (3) · Medical University of Vienna (3) · Ocugen (3) · Optall Vision (3) · Visus Therapeutics (3) · Wake Forest University Health Sciences (3) · Aristotle University Of Thessaloniki (2) · Bp Consulting, Inc (2) · CHA University (2) · Laboratorios Sophia S.A de C.V. (2)
United States (63) · South Korea (9) · Canada (8) · Germany (5) · Israel (5) · Brazil (4) · Italy (4) · Mexico (4) · Austria (3) · China (3) · France (3) · Portugal (3) · United Kingdom (3) · Australia (2) · Denmark (2)
James Teague, BS, Sr. Clinical Manager (3) · Steve Burmaster, PhD (3) · Alisyn Facemire, BA (2) · Cesar Alejandro S Galeana, MD (2) · Heleen DeCory (2) · Keith Walter, MD (2) · Aline K Sousa, MD (1) · Amandeep S Rai, MD (1) · Anastasios G Konstas, MD, PhD (1) · Anastasios Konstas, MD, phD (1) · Anat Robinson, MD (1) · Bianka Y Katayama, MD (1)
PMID 19476406, PMID 32134802, PMID 18402717, PMID 18534052, PMID 21960068, PMID 23579344, PMID 23839181, PMID 24212847, PMID 24709811, PMID 24886701, PMID 25429421, PMID 25430900, PMID 28663190, PMID 28785768, PMID 29461408, PMID 29680880, PMID 30573499, PMID 31799996, PMID 33383315, PMID 33389369, PMID 40711722, PMID 41737851, PMID 9261306
2015 (3), 2016 (1)